NexImmune reported financial results for Q2 2024, with net loss decreasing to $2.3 million compared to $7.6 million in Q2 2023. Research and development expenses declined to $0.6 million from $4.9 million, while general and administrative expenses decreased to $2.1 million from $2.9 million year-over-year. The company recorded a gain of $1.2 million from changes in warrant liability value.The company's cash and cash equivalents stood at $2.4 million as of June 30, 2024, which is expected to fund operations through Q3 2024. Following a strategic realignment, NexImmune has reduced its workforce to 6 full-time employees from 44 and is focusing resources on developing its AIM injectable platform for oncology and autoimmune diseases while pausing clinical trials of its adoptive cell therapy programs.Management is actively pursuing additional financing through public offerings, private placements...Show More

NexImmune reported financial results for Q2 2024, with net loss decreasing to $2.3 million compared to $7.6 million in Q2 2023. Research and development expenses declined to $0.6 million from $4.9 million, while general and administrative expenses decreased to $2.1 million from $2.9 million year-over-year. The company recorded a gain of $1.2 million from changes in warrant liability value.The company's cash and cash equivalents stood at $2.4 million as of June 30, 2024, which is expected to fund operations through Q3 2024. Following a strategic realignment, NexImmune has reduced its workforce to 6 full-time employees from 44 and is focusing resources on developing its AIM injectable platform for oncology and autoimmune diseases while pausing clinical trials of its adoptive cell therapy programs.Management is actively pursuing additional financing through public offerings, private placements, and strategic collaborations to extend its runway. However, the company noted substantial doubt about its ability to continue as a going concern and may seek stockholder approval for liquidation if unable to raise additional capital or achieve strategic alternatives. NexImmune's stock was delisted from Nasdaq in July 2024 and now trades on the OTC Pink Market.